1609-07-0

Basic information

• Product Name: N-cyano-N'-methylguanidine
• Synonyms: N-cyano-N'-methylguanidine;3-methylcyanoguanidine;[Amino(methylamino)methylene]amino cyanide;1-Cyano-3-methylguanidine
• CAS NO: 1609-07-0
• Molecular Formula: C₃H₆N₄
• Molecular Weight: 98.10654
• EINECS: 216-539-1
• Mol File: 1609-07-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 91-92 °C
• Boiling Point: 182.6 °C at 760 mmHg
• Flash Point: 64.2 °C
• Appearance: /
• Density: 1.18 g/cm³
• PKA: 3.09±0.70(Predicted)
• CAS DataBase Reference: N-cyano-N'-methylguanidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-cyano-N'-methylguanidine(1609-07-0)
• EPA Substance Registry System: N-cyano-N'-methylguanidine(1609-07-0)

Safety Data

• Hazardous Substances Data: 1609-07-0(Hazardous Substances Data)

Upstream product

• 5848-24-8 S-methyl-N-cyano-N'-methyl-carbamimidothioate 
• 593-51-1 methylamine hydrochloride 
• 1934-75-4 sodium dicyanamide 
• 71-36-3 butan-1-ol 
• 127099-85-8 N-Cyanoguanidine 
• 77-78-1 dimethyl sulfate 
• 7664-41-7 ammonia 
• 15760-26-6 3-cyano-2-methylisothiourea 
• 74-89-5 methylamine 

Downstream Products

• 60221-92-3 N¹-(p-Chlorphenyl)-N⁵-methylbiguanide 
• 108995-33-1 6,6,N⁴-trimethyl-1-phenyl-1,6-dihydro-[1,3,5]triazine-2,4-diyldiamine; hydrochloride 
• 106379-47-9 5-ethyl-2-imino-3-methyl-4,6-dioxo-5-phenyl-tetrahydro-pyrimidine-1-carbonitrile 
• 403603-20-3 N-(6-chloro-4-phenylquinazolin-2-yl)-N'-methylguanidinium p-toluenesulfonate 

Relevant articles and documents

Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome

Here we employed structure-based ligand discovery techniques to explore a recently determined crystal structure of the 5-hydroxytryptamine 2B (5-HT2B) receptor. Ten compounds containing a novel chemical scaffold were identified; among them, seven molecules were active in cellular function assays with the most potent one exhibiting an IC50 value of 27.3 nM. We then systematically probed the binding characteristics of this scaffold by designing, synthesizing, and testing a series of structural modifications. The structure-activity relationship studies strongly support our predicted binding model. The binding profiling across a panel of 11 5-HT receptors indicated that these compounds are highly selective for the 5-HT2B receptor. Oral administration of compound 15 (30 mg/kg) produced significant attenuation of visceral hypersensitivity in a rat model of irritable bowel syndrome (IBS). We expect this novel scaffold will serve as the foundation for the development of 5-HT2B antagonists for the treatment of IBS.

5-HT2B ANTAGONISTS

The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

APPLICATION OF PHOTOELECTRON SPECTROSCOPY TO BIOLOGICALLY ACTIVE MOLECULES AND THEIR CONSTITUENT PARTS. VII. N-CYANOAZOMETHINES

A series of N-cyanoazomethines 1-12 has been synthesized, and their electronic properties studied by He(I) photoelectron (PE) spectroscopy using the composite molecule approach.This allows partial assignment of the ionization energies in the PE spectrum of cimetidine 16, a known H2-receptor antagonist.Determination of differential UV spectra of the model compounds 7 and 13 revealed that no intramolecular charge transfer (CT) interaction exists between the two "ends" of the cimetidine molecule, i.e. between the ?-electron rich imidazole ring and the relatively ?-electron deficient cyanoguanidine moiety.